The lack of “shared understanding” between technology partners and clinical trialists is slowing progress in delivering the fully integrated, unified digital platforms that are needed to better support the use of decentralized clinical trials (DCTs).
Tech Vs Trialists: The Struggle For Integrated Decentralized Clinical Trial Platforms
The EU’s public-private Trials@Home Consortium examined what it would take to develop the fully integrated, unified digital platforms needed to enhance the implementation of decentralized clinical trials.
More from Europe
A draft royal decree would pave the way for more transparency in pricing and reimbursement decision-making processes and boost competition to increase the participation of generic medicines.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.
The European Medicines Agency says it will take appropriate measures to update the Ozempic’s package leaflet if new evidence arises.
Doxecitine/doxribtimine, UCB’s investigational orphan drug for pediatric and adult patients with thymidine kinase 2 deficiency, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
More from Geography
Final guidance on communicating scientific information on unapproved uses (SIUU) allows firm-generated presentations to be based on sources other than reprints, but says communications based on nonscientific content are not protected from enforcement.
A draft royal decree would pave the way for more transparency in pricing and reimbursement decision-making processes and boost competition to increase the participation of generic medicines.
Multiple industry groups in Japan warn that a decision to implement an "off-year" drug price revision in April will reverse other recent policy moves to support innovation.